CTCX Stock Overview
Operates as a bio-aesthetics company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Carmell Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.25 |
| 52 Week High | US$4.31 |
| 52 Week Low | US$0.20 |
| Beta | 0.31 |
| 11 Month Change | -29.86% |
| 3 Month Change | -65.24% |
| 1 Year Change | -91.82% |
| 33 Year Change | -97.47% |
| 5 Year Change | n/a |
| Change since IPO | -97.48% |
Recent News & Updates
Shareholder Returns
| CTCX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.8% | 2.5% | 2.2% |
| 1Y | -91.8% | 16.1% | 31.6% |
Return vs Industry: CTCX underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: CTCX underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| CTCX volatility | |
|---|---|
| CTCX Average Weekly Movement | 32.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTCX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CTCX's weekly volatility has increased from 22% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 10 | Kendra Bracken-Ferguson | www.carmellcosmetics.com |
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks.
Carmell Corporation Fundamentals Summary
| CTCX fundamental statistics | |
|---|---|
| Market cap | US$5.13m |
| Earnings (TTM) | -US$9.75m |
| Revenue (TTM) | US$32.84k |
156.3x
P/S Ratio-0.5x
P/E RatioIs CTCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTCX income statement (TTM) | |
|---|---|
| Revenue | US$32.84k |
| Cost of Revenue | US$5.13k |
| Gross Profit | US$27.71k |
| Other Expenses | US$9.77m |
| Earnings | -US$9.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 84.37% |
| Net Profit Margin | -29,675.45% |
| Debt/Equity Ratio | -8.9% |
How did CTCX perform over the long term?
See historical performance and comparison